Related Experiment Video
Updated: May 8, 2025
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
Translating CD47-targeted therapy in gastrointestinal cancers: Insights from preclinical to clinical studies
Changgan Chen1, Fengchun Lu1, Heguang Huang1
1Department of General Surgery, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou 350001, People's Republic of China.
Abstract:
This review presents a thorough investigation of the role of CD47 in gastrointestinal cancers. We performed a comprehensive, in-depth review of over 100 preclinical and clinical studies focused on inhibiting CD47. The research highlights the potential of targeted CD47 to enhance existing treatments by boosting the immune response to cancer cells. Considering the essential need to balance the toxicity and efficacy of CD47 inhibition, our review emphasizes the need to optimize CD47 inhibitors. We also demonstrate the necessity of combining CD47 antibodies with conventional chemotherapy, radiotherapy, or other targeted therapies to enhance treatment effectiveness. Finally, we propose the integration of CD47-targeted therapies into treatment plans as a promising approach to reshape the therapeutic landscape of gastrointestinal cancers. Continued research in this field holds great potential for improving the outcomes of gastrointestinal cancer patients and overcoming the challenges associated with this formidable spectrum of diseases.
Insights
Targeting CD47 (Cluster of Differentiation 47) shows promise in enhancing cancer treatments by boosting immune response. Optimizing CD47 inhibitors and combining them with other therapies is crucial for improving outcomes in gastrointestinal cancers.
Area of Science:
- Oncology
- Immunology
- Gastroenterology
Background:
- CD47 is a protein receptor implicated in immune evasion by cancer cells.
- Dysregulation of CD47 signaling is observed in various gastrointestinal cancers.
- Targeting CD47 presents a novel therapeutic strategy to overcome tumor-induced immune suppression.
Purpose of the Study:
- To comprehensively review the role of CD47 in gastrointestinal cancers.
- To evaluate the efficacy and safety of CD47 inhibition strategies.
- To explore combination therapies involving CD47-targeted agents.
Main Methods:
- Systematic review of over 100 preclinical and clinical studies.
- Analysis of research on CD47 inhibitors and their mechanisms of action.
- Evaluation of studies investigating combination therapies with CD47 antibodies.
Main Results:
- CD47 inhibition enhances anti-tumor immune responses.
- Optimizing CD47 inhibitors is essential to balance efficacy and toxicity.
- Combination therapies (chemotherapy, radiotherapy, targeted agents) with CD47 antibodies show improved effectiveness.
Conclusions:
- CD47-targeted therapies offer a promising approach to reshape gastrointestinal cancer treatment.
- Integration of CD47 inhibition into treatment plans can improve patient outcomes.
- Further research is needed to optimize CD47-targeted strategies for gastrointestinal malignancies.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
